<div id="readability-page-1"><div><p>As the U.S. stock market faces a challenging period with major indexes posting weekly losses and Treasury yields reaching a four-month high, investors are keenly observing potential opportunities in various sectors. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking growth prospects outside of the mainstream market giants. Despite being considered somewhat niche today, penny stocks can still offer significant potential when backed by robust financial health and strategic positioning within their industries.</p><h3>Top 10 Penny Stocks In The United States</h3><table><tbody><tr><td><strong>Name</strong></td><td><strong>Share Price</strong></td><td><strong>Market Cap</strong></td><td><strong>Rewards &amp; Risks</strong></td></tr><tr><td>Dingdong (Cayman) (DDL)</td><td>$2.61</td><td>$559.34M</td><td>✅ 4 ⚠️ 1 View Analysis &gt;</td></tr><tr><td>Waterdrop (WDH)</td><td>$1.79</td><td>$647.38M</td><td>✅ 4 ⚠️ 0 View Analysis &gt;</td></tr><tr><td>WM Technology (MAPS)</td><td>$0.825</td><td>$141.09M</td><td>✅ 4 ⚠️ 1 View Analysis &gt;</td></tr><tr><td>LexinFintech Holdings (LX)</td><td>$3.00</td><td>$504.79M</td><td>✅ 4 ⚠️ 2 View Analysis &gt;</td></tr><tr><td>Tuya (TUYA)</td><td>$2.25</td><td>$1.36B</td><td>✅ 4 ⚠️ 1 View Analysis &gt;</td></tr><tr><td>CI&amp;T (CINT)</td><td>$4.73</td><td>$614.03M</td><td>✅ 5 ⚠️ 0 View Analysis &gt;</td></tr><tr><td>Golden Growers Cooperative (GGRO.U)</td><td>$5.00</td><td>$77.45M</td><td>✅ 1 ⚠️ 5 View Analysis &gt;</td></tr><tr><td>Cricut (CRCT)</td><td>$4.31</td><td>$912.62M</td><td>✅ 2 ⚠️ 2 View Analysis &gt;</td></tr><tr><td>BAB (BABB)</td><td>$0.91</td><td>$6.61M</td><td>✅ 2 ⚠️ 3 View Analysis &gt;</td></tr><tr><td>Lifetime Brands (LCUT)</td><td>$3.90</td><td>$88.36M</td><td>✅ 3 ⚠️ 2 View Analysis &gt;</td></tr></tbody></table><p>Click here to see the full list of 334 stocks from our  US Penny Stocks screener.</p><p>Let's review some notable picks from our screened stocks.</p><h2>ATA Creativity Global (AACG)</h2><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> ATA Creativity Global, along with its subsidiaries, offers educational services both in China and internationally, with a market cap of $36.84 million.</p><p><strong>Operations:</strong> The company's revenue segments include CN¥256.91 million from Segment Adjustment and CN¥22.99 million from Other Educational Services.</p><p><strong>Market Cap:</strong> $36.84M</p><p>ATA Creativity Global, with a market cap of $36.84 million, has shown improvement in its financials despite being unprofitable. The company reduced its net loss significantly over the past year and reported a net income of CN¥2.37 million for Q3 2025, compared to a net loss previously. Its short-term assets exceed long-term liabilities but fall short against short-term liabilities, highlighting potential liquidity concerns. Recent efforts to raise $8.85 million through equity offerings suggest ongoing capital needs. While the management and board are seasoned, the stock remains highly volatile with decreased weekly volatility from 18% to 12%.</p><ul><li>Click here and access our complete financial health analysis report to understand the dynamics of ATA Creativity Global.</li><li>Understand ATA Creativity Global's track record by examining our performance history report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/72e41983-3668-429b-8c7c-04ae55a7571c/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/72e41983-3668-429b-8c7c-04ae55a7571c/chart/debt-equity-history-analysis"/><figcaption>AACG Debt to Equity History and Analysis as at Jan 2026</figcaption></figure><h2>Aldeyra Therapeutics (ALDX)</h2><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p><p><strong>Overview:</strong> Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated and metabolic diseases, with a market cap of approximately $278.55 million.</p><p><strong>Operations:</strong> Aldeyra Therapeutics, Inc. has not reported any revenue segments.</p><p><strong>Market Cap:</strong> $278.55M</p><p>Aldeyra Therapeutics, with a market cap of US$278.55 million, is pre-revenue and remains unprofitable, yet it has managed to reduce its losses over the past five years. The company recently faced an FDA extension for its reproxalap NDA due to additional data requests but received no major deficiencies from the agency. Aldeyra's cash position exceeds its total debt, providing a sufficient runway for operations beyond a year. Despite high share price volatility and negative return on equity, Aldeyra's seasoned management and board offer stability as it pursues advancements in immune-mediated therapies.</p><ul><li>Get an in-depth perspective on Aldeyra Therapeutics' performance by reading our balance sheet health report here.</li><li>Learn about Aldeyra Therapeutics' future growth trajectory here.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55e4738e-9ff5-4d4f-8334-fd9b51fc6541/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55e4738e-9ff5-4d4f-8334-fd9b51fc6541/chart/debt-equity-history-analysis"/><figcaption>ALDX Debt to Equity History and Analysis as at Jan 2026</figcaption></figure><h2>MediciNova (MNOV)</h2><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p><p><strong>Overview:</strong> MediciNova, Inc. is a biopharmaceutical company that develops novel small molecule therapeutics for serious diseases with unmet medical needs in the United States, with a market cap of $78.63 million.</p><p><strong>Operations:</strong> MediciNova, Inc. does not report any revenue segments.</p><p><strong>Market Cap:</strong> $78.63M</p><p>MediciNova, with a market cap of US$78.63 million, is pre-revenue and unprofitable but has reduced losses over the past five years. The company recently completed patient enrollment for its Phase 2 OXTOX study and Phase 2b/3 COMBAT-ALS trial, both utilizing MN-166 (ibudilast), which has Orphan Drug Designation from the FDA and EMA. Despite high share price volatility, MediciNova's seasoned management team provides stability as it advances its pipeline in neurodegenerative diseases. A recent follow-on equity offering of US$50 million aims to bolster financial resources amid ongoing clinical developments.</p><ul><li>Navigate through the intricacies of MediciNova with our comprehensive balance sheet health report here.</li><li>Assess MediciNova's future earnings estimates with our detailed growth reports.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7e64759a-aaa7-429b-bb54-bf40a8c048cc/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7e64759a-aaa7-429b-bb54-bf40a8c048cc/chart/financial-position-analysis"/><figcaption>MNOV Financial Position Analysis as at Jan 2026</figcaption></figure><h2>Taking Advantage</h2><ul><li>Embark on your investment journey to our 334  US Penny Stocks selection here.</li><li>Want To Explore Some Alternatives? Find companies with promising cash flow potential yet trading below their fair value.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation. We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

ALDX

MNOV

AACG

<p>ATA Creativity Global is highlighted as one of three promising penny stocks amid a challenging U.S. stock market. The company, with a market cap of $36.84 million, offers educational services and has shown improved financials, reducing its net loss significantly. Despite liquidity concerns, it raised $8.85 million through equity offerings. The stock remains volatile but has decreased in weekly volatility. Other notable penny stocks include Aldeyra Therapeutics and MediciNova, both in the biotech sector, focusing on therapies for unmet medical needs and showing potential for growth despite being unprofitable.</p>

ATA Creativity Global Among 3 Promising Penny Stocks